Dr. Michael Kallos

Associate Director of the Pharmaceutical Production Research Facility (PPRF) and Professor, University of Calgary

Dr. Michael Kallos is a Professor in the Department of Chemical and Petroleum Engineering, Schulich School of Engineering, an Adjunct in the Department of Cell Biology and Anatomy in the Cumming School of Medicine, and Associate Director of the Pharmaceutical Production Research Facility (PPRF), all at the University of Calgary. He is the Director of the Biomedical Engineering (BME) Calgary Initiative and Associate Director of the Center for Bioengineering Research and Education (CBRE), as well as a member of the McCaig Institute for Bone and Joint Health. The Biomedical Engineering Calgary Initiative at the University of Calgary, bringing together over 300 researchers from multiple faculties across campus to tackle problems in human and animal health and wellness. He is a Professional Engineer registered with APEGA. His research interests lie in the area of stem cell bioprocess engineering, including working with ESCs, iPSCs, MSCs and NSCs. He bases his research on a strong foundation in mass transfer, reactor design, reaction kinetics, fluid dynamics and experience in both experimental and modeling approaches. These fundamentals are key to the industrial/clinical scale-up and production of cell and biomaterial therapies.

Scaling Up Cell Production for Clinical Trials

Wednesday, September 11, 9:00 AM – 9:30 AM


Equine mesenchymal stromal cells (MSCs) are increasingly investigated for their clinical therapeutic utility. Such cell-based treatments can require cell numbers in the millions or billions, with conventional expansion methods using static T-flasks typically inefficient in achieving these cell numbers. Equine cord blood-derived MSCs (eCB-MSCs), are promising cell candidates owing to their capacity for chondrogenic differentiation and immunomodulation. Expansion of eCB-MSCs in stirred suspension bioreactors with microcarriers as an attachment surface has the potential to generate clinically relevant numbers of cells while decreasing cost, time and labor requirements and increasing reproducibility and yield when compared to static expansion. As eCB-MSCs have not yet been expanded in stirred suspension bioreactors, a robust protocol was required to expand these cells using this method. This study outlines the development of an expansion bioprocess, detailing the inoculation phase, expansion phase, and harvesting phase, followed by phenotypic and trilineage differentiation characterization of two eCB-MSC donors. When compared to cells grown in static T-flasks, bioreactor-expanded eCB-MSC cultures did not change in surface marker expression or trilineage differentiation capacity. This indicates that the bioreactor expansion process yields large quantities of eCB-MSCs with similar characteristics to conventionally grown eCB-MSCs.